Haisco licenses two drug candidates to Nuvectis for $40m upfront
Haisco licenses two drug candidates to Nuvectis for $40m upfront
Haisco licenses two drug candidates to Nuvectis for $40m upfront
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.